A link between hepatic glucose production and peripheral energy metabolism via hepatokines

Molecular Metabolism

Volumn 3, Issue 5, 2014, Pages 531-543

  Abdul Wahed, Aya ^a,b,c,d   Gautier Stein, Amandine ^a,b,c   Casteras, Sylvie ^a,b,c   Soty, Maud ^a,b,c   Roussel, Damien ^b,c,e   Romestaing, Caroline ^b,c,e   Guillou, Hervé ^f   Tourette, Jean André ^a,b,c   Pleche, Nicolas ^a,b,c   Zitoun, Carine ^a,b,c   Gri, Blandine ^a,b,c   Sardella, Anne ^a,b,c   Rajas, Fabienne ^a,b,c   Mithieux, Gilles ^a,b,c  

^a INSTITUT NATIONAL DE LA SANTÉ ET DE LA RECHERCHE MÉDICALE   (France)

^b UNIVERSITÉ DE LYON   (France)

^c UNIVERSITÉ LYON 1   (France)

^d UNIVERSITY OF ALEPPO   (Syrian Arab Republic)

^e CNRS   (France)

^f TOXALIM RESEARCH CENTRE IN FOOD TOXICOLOGY   (France)

Author keywords

Endogenous glucose production; Energy expenditure; Hepatokines; Liver; Obesity; Type 2 diabetes

Indexed keywords

ADIPONECTIN; ANGIOPOIETIN; ANGIOPOIETIN GROWTH FACTOR 3; ANGIOPOIETIN LIKE FACTOR 6; CARBOHYDRATE RESPONSE ELEMENT BINDING PROTEIN; CD36 ANTIGEN; CYTOCHROME C OXIDASE; CYTOKINE; FAT; FETUIN A; FIBROBLAST GROWTH FACTOR 21; GEPATIC GROWTH FACTOR; GLUCOSE; GLUCOSE 6 PHOSPHATASE; HEPATOKINE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE KINASE; INSULIN; MITOGEN ACTIVATED PROTEIN KINASE P38; MYOSIN HEAVY CHAIN; MYOSIN HEAVY CHAIN 1; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR DELTA; SELENOPROTEIN P; SOMATOMEDIN C; SUCROSE; TAMOXIFEN; TRIACYLGLYCEROL; UNCLASSIFIED DRUG; UNCOUPLING PROTEIN 2; UNCOUPLING PROTEIN 3;

ACACA GENE; ACOX1 GENE; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BODY WEIGHT; BROWN ADIPOSE TISSUE; CD36 GENE; CONTROLLED STUDY; COX4 GENE; CPT1B GENE; CYT1B GENE; CYTCS GENE; CYTSC GENE; DIABETES MELLITUS; ENERGY EXPENDITURE; ENERGY METABOLISM; EXERCISE; FASN GENE; FATTY ACID OXIDATION; GENE; GENE DELETION; GENE OVEREXPRESSION; GLUCONEOGENESIS; GLUCOSE METABOLISM; HIGH SUCROSE DIET; HOMEOSTASIS; HORMONE RELEASE; INSULIN RESISTANCE; INSULIN SENSITIVITY; LIPID DIET; LIVER; LPL GENE; MALE; MITOCHONDRIAL RESPIRATION; MOUSE; NONHUMAN; OBESITY; PATHOPHYSIOLOGY; PKLR GENE; PPAR GENE; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; THERMOGENESIS; UCP2 GENE; UCP3 GENE; UPREGULATION; WHITE ADIPOSE TISSUE;

MUS;

EID: 84904292910     PISSN: 22128778     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.molmet.2014.05.005     Document Type: Article

References (74)

1. Chen L., Magliano D.J., Zimmet P.Z. The worldwide epidemiology of type 2 diabetes mellitus - present and future perspectives. Nature Reviews Endocrinology 2012, 8:228-236.
2. DeFronzo R.A. Pathogenesis of type 2 diabetes mellitus. Medical Clinics of North America 2004, 88:787-835. ix.
3. Granner D.K., O'Brien R.M. Molecular physiology and genetics of NIDDM. Importance of metabolic staging. Diabetes Care 1992, 15:369-395.
4. Weyer C., Bogardus C., Mott D.M., Pratley R.E. The natural history of insulin secretory dysfunction and insulin resistance in the pathogenesis of type 2 diabetes mellitus. The Journal of Clinical Investigation 1999, 104:787-794.
5. Lauro D., Kido Y., Castle A.L., Zarnowski M.J., Hayashi H., Ebina Y., et al. Impaired glucose tolerance in mice with a targeted impairment of insulin action in muscle and adipose tissue. Nature Genetics 1998, 20:294-298.
6. Clore J.N., Stillman J., Sugerman H. Glucose-6-phosphatase flux invitro is increased in type 2 diabetes. Diabetes 2000, 49:969-974.
7. Consoli A., Nurjhan N., Capani F., Gerich J. Predominant role of gluconeogenesis in increased hepatic glucose production in NIDDM. Diabetes 1989, 38:550-557.
8. Home P.D., Pacini G. Hepatic dysfunction and insulin insensitivity intype 2 diabetes mellitus: a critical target for insulin-sensitizing agents. Diabetes, Obesity and Metabolism 2008, 10:699-718.
9. Magnusson I., Rothman D.L., Katz L.D., Shulman R.G., Shulman G.I. Increased rate of gluconeogenesis in type II diabetes mellitus. A 13C nuclearmagnetic resonance study. The Journal of Clinical Investigation 1992, 90:1323-1327.
10. Rizza R.A. Pathogenesis of fasting and postprandial hyperglycemia in type 2 diabetes: implications for therapy. Diabetes 2010, 59:2697-2707.
11. Roden M., Petersen K.F., Shulman G.I. Nuclear magnetic resonance studies of hepatic glucose metabolism in humans. Recent Progress in Hormone Research 2001, 56:219-237.
12. Altarejos J.Y., Montminy M. CREB and the CRTC co-activators: sensors for hormonal and metabolic signals. Nature Reviews Molecular Cell Biology 2011, 12:141-151.
13. Del Prato S., Marchetti P. Beta- and alpha-cell dysfunction in type 2 diabetes. Hormone and Metabolic Research 2004, 36:775-781.
14. Mithieux G., Rajas F., Gautier-Stein A. Anovel role for glucose 6-phosphatase in the small intestine in the control of glucose homeostasis. The Journal of Biological Chemistry 2004, 279:44231-44234.
15. Delaere F., Magnan C., Mithieux G. Hypothalamic integration of portal glucose signals and control of food intake and insulin sensitivity. Diabetes & Metabolism 2010, 36:257-262.
16. Mithieux G. Nutrient control of hunger by extrinsic gastrointestinal neurons. Trends in Endocrinology & Metabolism (TEM) 2013, 24:378-384.
17. Duraffourd C., De Vadder F., Goncalves D., Delaere F., Penhoat A., Brusset B., et al. Mu-opioid receptors and dietary protein stimulate a gut-brain neural circuitry limiting food intake. Cell 2012, 150:377-388.
18. Pillot B., Soty M., Gautier-Stein A., Zitoun C., Mithieux G. Proteinfeeding promotes redistribution of endogenous glucose production tothe kidney and potentiates its suppression by insulin. Endocrinology 2009, 150:616-624.
19. De Vadder F., Kovatcheva-Datchary P., Goncalves D., Vinera J., Zitoun C., Duchampt A., et al. Microbiota-generated metabolites promote metabolic benefits via gut-brain neural circuits. Cell 2014, 156:84-96.
20. Mutel E., Gautier-Stein A., Abdul-Wahed A., Amigó-Correig M., Zitoun C., Stefanutti A., et al. Control of blood glucose in the absence of hepatic glucose production during prolonged fasting in mice: induction of renal and intestinal gluconeogenesis by glucagon. Diabetes 2011, 60:3121-3131.
21. Mutel E., Abdul-Wahed A., Ramamonjisoa N., Stefanutti A., Houberdon I., Cavassila S., et al. Targeted deletion of liver glucose-6 phosphatase mimics glycogen storage disease type 1a including development of multiple adenomas. Journal of Hepatology 2011, 54:529-537.
22. Potthoff M.J., Inagaki T., Satapati S., Ding X., He T., Goetz R., et al. FGF21 induces PGC-1alpha and regulates carbohydrate and fatty acid metabolism during the adaptive starvation response. Proceedings of the National Academy of Sciences of the United States of America 2009, 106:10853-10858.
23. Wetter T.J., Gazdag A.C., Dean D.J., Cartee G.D. Effect of calorie restriction on invivo glucose metabolism by individual tissues in rats. American Journal of Physiology 1999, 276:E728-E738.
24. Pfleiderer G. Glycogen: determination with amyloglucosidase. Methods enzym. anal. 1974, 59-62. Bergmeyer HU, Deerfield Beach, FL, US. 2nd ed.
25. Rajas F., Jourdan-Pineau H., Stefanutti A., Mrad E.A., Iynedjian P.B., Mithieux G. Immunocytochemical localization of glucose 6-phosphatase and cytosolic phosphoenolpyruvate carboxykinase in gluconeogenic tissues reveals unsuspected metabolic zonation. Histochemistry and Cell Biology 2007, 127:555-565.
26. Luquet S., Lopez-Soriano J., Holst D., Fredenrich A., Melki J., Rassoulzadegan M., et al. Peroxisome proliferator-activated receptor delta controls muscle development and oxidative capability. FASEB Journal: Official Publication of the Federation of American Societies for Experimental Biology 2003, 17:2299-2301.
27. Mithieux G., Gautier-Stein A., Rajas F., Zitoun C. Contribution of intestine and kidney to glucose fluxes in different nutritional states in rat. Comparative Biochemistry and Physiology Part B: Biochemistry and Molecular Biology 2006, 143:195-200.
28. Postic C., Girard J. Contribution of de novo fatty acid synthesis to hepatic steatosis and insulin resistance: lessons from genetically engineered mice. The Journal of Clinical Investigation 2008, 118:829-838.
29. Ramamonjisoa N., Ratiney H., Mutel E., Guillou H., Mithieux G., Pilleul F., et al. Invivo hepatic lipid quantification using MRS at 7 Tesla in a mouse model of glycogen storage disease type 1a. Journal of Lipid Research 2013, 54:2010-2022.
30. Lowell B.B., Spiegelman B.M. Towards a molecular understanding of adaptive thermogenesis. Nature 2000, 404:652-660.
31. Evans R.M., Barish G.D., Wang Y.-X. PPARs and the complex journey to obesity. Nature Medicine 2004, 10:355-361.
32. Pogozelski A.R., Geng T., Li P., Yin X., Lira V.A., Zhang M., et al. p38gamma mitogen-activated protein kinase is a key regulator in skeletal muscle metabolic adaptation in mice. PloS One 2009, 4:e7934.
33. Viollet B., Lantier L., Devin-Leclerc J., Hebrard S., Amouyal C., Mounier R., et al. Targeting the AMPK pathway for the treatment of type 2 diabetes. Frontiers in Bioscience (Landmark Edition) 2009, 14:3380-3400.
34. Ehrenborg E., Krook A. Regulation of skeletal muscle physiology and metabolism by peroxisome proliferator-activated receptor delta. Pharmacological Reviews 2009, 61:373-393.
35. Olesen J., Kiilerich K., Pilegaard H. PGC-1alpha-mediated adaptationsin skeletal muscle. Pflügers Archiv: European Journal of Physiology 2010, 460:153-162.
36. Imai J., Katagiri H., Yamada T., Ishigaki Y., Suzuki T., Kudo H., et al. Regulation of pancreatic beta cell mass by neuronal signals from the liver. Science 2008, 322:1250-1254.
37. Uno K., Katagiri H., Yamada T., Ishigaki Y., Ogihara T., Imai J., et al. Neuronal pathway from the liver modulates energy expenditure and systemic insulin sensitivity. Science 2006, 312:1656-1659.
38. Troy S., Soty M., Ribeiro L., Laval L., Migrenne S., Fioramonti X., et al. Intestinal gluconeogenesis is a key factor for early metabolic changes after gastric bypass but not after gastric lap-band in mice. Cell Metabolism 2008, 8:201-211.
39. Oike Y., Akao M., Kubota Y., Suda T. Angiopoietin-like proteins: potential new targets for metabolic syndrome therapy. Trends in Molecular Medicine 2005, 11:473-479.
40. Kumar K.G., Trevaskis J.L., Lam D.D., Sutton G.M., Koza R.A., Chouljenko V.N., et al. Identification of adropin as a secreted factor linking dietary macronutrient intake with energy homeostasis and lipid metabolism. Cell Metabolism 2008, 8:468-481.
41. Perdomo G., Martinez-Brocca M.A., Bhatt B.A., Brown N.F., O'Doherty R.M., Garcia-Ocaña A. Hepatocyte growth factor is a novel stimulator of glucose uptake and metabolism in skeletal muscle cells. The Journal of Biological Chemistry 2008, 283:13700-13706.
42. Stefan N., Häring H.-U. Circulating fetuin-A and free fatty acidsinteract to predict insulin resistance in humans. Nature Medicine 2013, 19:394-395.
43. Habegger K.M., Stemmer K., Cheng C., Muller T.D., Heppner K.M., Ottaway N., et al. Fibroblast growth factor 21 mediates specific glucagon actions. Diabetes 2013, 62:1453-1463.
44. Badman M.K., Pissios P., Kennedy A.R., Koukos G., Flier J.S., Maratos-Flier E. Hepatic fibroblast growth factor 21 is regulated by PPARalpha and is a key mediator of hepatic lipid metabolism in ketotic states. Cell Metabolism 2007, 5:426-437.
45. Kharitonenkov A., Larsen P. FGF21 reloaded: challenges of a rapidly growing field. Trends in Endocrinology & Metabolism (TEM) 2011, 22:81-86.
46. Kharitonenkov A., Shiyanova T.L., Koester A., Ford A.M., Micanovic R., Galbreath E.J., et al. FGF-21 as a novel metabolic regulator. The Journal of Clinical Investigation 2005, 115:1627-1635.
47. Berglund E.D., Li C.Y., Bina H.A., Lynes S.E., Michael M.D., Shanafelt A.B., et al. Fibroblast growth factor 21 controls glycemia via regulation of hepatic glucose flux and insulin sensitivity. Endocrinology 2009, 150:4084-4093.
48. Coskun T., Bina H.A., Schneider M.A., Dunbar J.D., Hu C.C., Chen Y., et al. Fibroblast growth factor 21 corrects obesity in mice. Endocrinology 2008, 149:6018-6027.
49. Li Y., Wong K., Giles A., Jiang J., Lee J.W., Adams A.C., et al. Hepatic SIRT1 attenuates hepatic steatosis and controls energy balance inmice by inducing fibroblast growth factor 21. Gastroenterology 2014, 146:539-549.
50. Xu J., Lloyd D.J., Hale C., Stanislaus S., Chen M., Sivits G., et al. Fibroblast growth factor 21 reverses hepatic steatosis, increases energy expenditure, and improves insulin sensitivity in diet-induced obese mice. Diabetes 2009, 58:250-259.
51. Oike Y., Akao M., Yasunaga K., Yamauchi T., Morisada T., Ito Y., et al. Angiopoietin-related growth factor antagonizes obesity and insulin resistance. Nature Medicine 2005, 11:400-408.
52. Uebanso T., Taketani Y., Yamamoto H., Amo K., Ominami H., Arai H., et al. Paradoxical regulation of human FGF21 by both fasting and feeding signals: is FGF21 a nutritional adaptation factor?. PloS One 2011, 6:e22976.
53. Filhoulaud G., Guilmeau S., Dentin R., Girard J., Postic C. Novel insights into ChREBP regulation and function. Trends in Endocrinology & Metabolism (TEM) 2013, 24:257-268.
54. Dentin R., Tomas-Cobos L., Foufelle F., Leopold J., Girard J., Postic C., et al. Glucose 6-phosphate, rather than xylulose 5-phosphate, is required for the activation of ChREBP in response to glucose in the liver. Journal of Hepatology 2012, 56:199-209.
55. Herman M.A., Peroni O.D., Villoria J., Schön M.R., Abumrad N.A., Blüher M., et al. Anovel ChREBP isoform in adipose tissue regulates systemic glucose metabolism. Nature 2012, 484:333-338.
56. Dressel U., Allen T.L., Pippal J.B., Rohde P.R., Lau P., Muscat G.E.O. The peroxisome proliferator-activated receptor beta/delta agonist, GW501516, regulates the expression of genes involved in lipid catabolism and energy uncoupling in skeletal muscle cells. Molecular Endocrinology 2003, 17:2477-2493.
57. Tanaka T., Yamamoto J., Iwasaki S., Asaba H., Hamura H., Ikeda Y., et al. Activation of peroxisome proliferator-activated receptor delta induces fatty acid beta-oxidation in skeletal muscle and attenuates metabolic syndrome. Proceedings of the National Academy of Sciences of the United States of America 2003, 100:15924-15929.
58. Wang Y.-X., Lee C.-H., Tiep S., Yu R.T., Ham J., Kang H., et al. Peroxisome-proliferator-activated receptor delta activates fat metabolism to prevent obesity. Cell 2003, 113:159-170.
59. Shulman G.I. Cellular mechanisms of insulin resistance. The Journal of Clinical Investigation 2000, 106:171-176.
60. Taylor E.B., An D., Kramer H.F., Yu H., Fujii N.L., Roeckl K.S.C., et al. Discovery of TBC1D1 as an insulin-, AICAR-, and contraction-stimulated signaling nexus in mouse skeletal muscle. The Journal of Biological Chemistry 2008, 283:9787-9796.
61. Xi X., Han J., Zhang J.Z. Stimulation of glucose transport by AMP-activated protein kinase via activation of p38 mitogen-activated protein kinase. The Journal of Biological Chemistry 2001, 276:41029-41034.
62. Mithieux G., Guignot L., Bordet J.-C., Wiernsperger N. Intrahepatic mechanisms underlying the effect of metformin in decreasing basal glucose production in rats fed a high-fat diet. Diabetes 2002, 51:139-143.
63. Musi N., Hirshman M.F., Nygren J., Svanfeldt M., Bavenholm P., Rooyackers O., et al. Metformin increases AMP-activated protein kinase activity in skeletal muscle of subjects with type 2 diabetes. Diabetes 2002, 51:2074-2081.
64. Mithieux G. Metformin and the gut function. Metformin mech. insights new appl. 2008, 31-40. Transworld Research Network, Kerala, India.
65. Grefhorst A., Schreurs M., Oosterveer M.H., Cortés V.A., Havinga R., Herling A.W., et al. Carbohydrate-response-element-binding protein (ChREBP) and not the liver X receptor α (LXRα) mediates elevated hepatic lipogenic gene expression in a mouse model of glycogen storage disease type 1. The Biochemical Journal 2010, 432:249-254.
66. Sun Z., Lazar M.A. Dissociating fatty liver and diabetes. Trends in Endocrinology & Metabolism (TEM) 2013, 24:4-12.
67. Sun Z., Miller R.A., Patel R.T., Chen J., Dhir R., Wang H., et al. Hepatic Hdac3 promotes gluconeogenesis by repressing lipid synthesis and sequestration. Nature Medicine 2012, 18:934-942.
68. Fisher F.M., Kleiner S., Douris N., Fox E.C., Mepani R.J., Verdeguer F., et al. FGF21 regulates PGC-1α and browning of white adipose tissues in adaptive thermogenesis. Genes & Development 2012, 26:271-281.
69. Ge X., Chen C., Hui X., Wang Y., Lam K.S.L., Xu A. Fibroblast growth factor 21 induces glucose transporter-1 expression through activation of the serum response factor/Ets-like protein-1 in adipocytes. The Journal of Biological Chemistry 2011, 286:34533-34541.
70. Kharitonenkov A., Adams A.C. Inventing new medicines: the FGF21 story. Molecular Metabolism 2014, 3:221-229.
71. Gaich G., Chien J.Y., Fu H., Glass L.C., Deeg M.A., Holland W.L., et al. The effects of LY2405319, an FGF21 analog, in obese human subjects with type 2 diabetes. Cell Metabolism 2013, 18:333-340.
72. Huang J., Ishino T., Chen G., Rolzin P., Osothprarop T.F., Retting K., et al. Development of a novel long-acting antidiabetic FGF21 mimetic by targeted conjugation to a scaffold antibody. Journal of Pharmacology and Experimental Therapeutics 2013, 346:270-280.
73. Müller T.D., Sullivan L.M., Habegger K., Yi C.-X., Kabra D., Grant E., et al. Restoration of leptin responsiveness in diet-induced obese mice using an optimized leptin analog in combination with exendin-4 or FGF21. Journal of Peptide Science: An Official Publication of the European Peptide Society 2012, 18:383-393.
74. Tschöp M.H., DiMarchi R.D. Outstanding scientific achievement award lecture 2011: defeating diabesity: the case for personalized combinatorial therapies. Diabetes 2012, 61:1309-1314.